Datavant and Prognos collaborate for a ‘more comprehensive view of the patient’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: Data, data analysis, Data management, analytical, analytics, Clinical research, Clinical data, Clinical data management

Datavant enters partnership with Prognos to expand the latter’s analytics capabilities to determine clinical outcomes and inform decision making as data availability grows.

Through the partnership, Prognos, a company focused on providing analytics for disease prediction, will tap Datavant’s data ecosystem to expand its data and analytics, for its customers to make informed clinical decisions and identify any potential risks.

Datavant’s technology used in this agreement has been specifically designed to allow data sharing while still protecting patient privacy. This collaboration will also see Datavant’s data ecosystem grow, as Prognos’ existing data source partners and customers will be given the option to connect information to the company’s system.

A spokesperson for Datavant told us that Prognos’ product “only becomes more powerful when [it] can draw on data from additional sources. By replacing Prognos’ existing de-identification and linking the solution with Datavant’s, Prognos has the ability to form additional source relationships and integrate that data with what they already have.”

Using this analytical platform from Datavant, Prognos will be able to determine and predict trends in disease progression and provide health care companies with clinical insights to go alongside traditional medical claims.  

According to Sundeep Bhan, CEO and co-founder of Prognos, the analytical capabilities created from this agreement will give its customers “a more comprehensive view of the patient”​ and will enable more forward-looking insights to improve decision-making.

Bhan added, “As the amount of health care data exponentially increases, so does our potential for predicting disease and its trajectory, which enables us to get the right treatment and care to the right patient, at the right time.”

Currently, Prognos’ registry of laboratory results contains 24bn records covering 200m patients across more than 50 diseases. The company also has 1,000 proprietary clinical algorithms for patient identification and treatment decision making, risk management, and quality improvement.

Per the agreement, Datavant will also acquire Prognos’ OPAL product, a de-identification solution for diagnostic data. Users of the product will be migrated onto Datavant’s ecosystem and will have access to the company’s partners.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more